Christopher S. Hourigan, Lisanne Beugelink, Jad Othman, Gege Gui, Adam Ivey, Richard Dillon, Christian Thiede, Mark J. Levis, Laura W. Dillon, Andrew H Wei, Ing Soo Tiong, Sun Loo, Konstanze Döhner, Isabell Arnhardt, Artur Kowalik, Nicola Potter, D H Kim, Claude Preudhomme, Nicolas Duployez, Michael Heuser, Peter JM Valk
FLT3-ITD measurable residual disease (MRD) testing for patients in remission from acute myeloid leukemia (AML) is now recommended by the recently updated clinical standard of care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.